Unknown

Dataset Information

0

The tyrosine kinase v-Src modifies cytotoxicities of anticancer drugs targeting cell division.


ABSTRACT: v-Src oncogene causes cell transformation through its strong tyrosine kinase activity. We have revealed that v-Src-mediated cell transformation occurs at a low frequency and it is attributed to mitotic abnormalities-mediated chromosome instability. v-Src directly phosphorylates Tyr-15 of cyclin-dependent kinase 1 (CDK1), thereby causing mitotic slippage and reduction in Eg5 inhibitor cytotoxicity. However, it is not clear whether v-Src modifies cytotoxicities of the other anticancer drugs targeting cell division. In this study, we found that v-Src restores cancer cell viability reduced by various microtubule-targeting agents (MTAs), although v-Src does not alter cytotoxicity of DNA-damaging anticancer drugs. v-Src causes mitotic slippage of MTAs-treated cells, consequently generating proliferating tetraploid cells. We further demonstrate that v-Src also restores cell viability reduced by a polo-like kinase 1 (PLK1) inhibitor. Interestingly, treatment with Aurora kinase inhibitor strongly induces cell death when cells express v-Src. These results suggest that the v-Src modifies cytotoxicities of anticancer drugs targeting cell division. Highly activated Src-induced resistance to MTAs through mitotic slippage might have a risk to enhance the malignancy of cancer cells through the increase in chromosome instability upon chemotherapy using MTAs.

SUBMITTER: Yuki R 

PROVIDER: S-EPMC7875926 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5482733 | biostudies-literature
| S-EPMC7912711 | biostudies-literature
| S-EPMC23901 | biostudies-literature
| S-EPMC7215861 | biostudies-literature
| S-EPMC4936181 | biostudies-literature
| S-EPMC5682962 | biostudies-literature
| S-EPMC6602532 | biostudies-literature
| S-EPMC2133004 | biostudies-literature
| S-EPMC5573332 | biostudies-literature
| S-EPMC4792907 | biostudies-literature